annual CFF:
-$5.76M-$38.25M(-117.73%)Summary
- As of today (June 3, 2025), BCRX annual cash flow from financing activities is -$5.76 million, with the most recent change of -$38.25 million (-117.73%) on December 31, 2024.
- During the last 3 years, BCRX annual CFF has fallen by -$365.43 million (-101.60%).
- BCRX annual CFF is now -101.60% below its all-time high of $359.67 million, reached on December 31, 2021.
Performance
BCRX Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$529.00K+$4.55M(+113.16%)Summary
- As of today (June 3, 2025), BCRX quarterly cash flow from financing activities is $529.00 thousand, with the most recent change of +$4.55 million (+113.16%) on March 31, 2025.
- Over the past year, BCRX quarterly CFF has increased by +$1.58 million (+150.48%).
- BCRX quarterly CFF is now -99.85% below its all-time high of $347.42 million, reached on December 31, 2021.
Performance
BCRX quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$4.18M+$1.58M(+27.37%)Summary
- As of today (June 3, 2025), BCRX TTM cash flow from financing activities is -$4.18 million, with the most recent change of +$1.58 million (+27.37%) on March 31, 2025.
- Over the past year, BCRX TTM CFF has dropped by -$30.54 million (-115.87%).
- BCRX TTM CFF is now -100.97% below its all-time high of $431.25 million, reached on September 30, 2022.
Performance
BCRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
BCRX Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -117.7% | +150.5% | -115.9% |
| 3 y3 years | -101.6% | -92.8% | -101.2% |
| 5 y5 years | -105.8% | +98.9% | -105.3% |
BCRX Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -101.6% | at low | -99.3% | +113.2% | -101.0% | +27.4% |
| 5 y | 5-year | -101.6% | at low | -99.8% | +111.4% | -101.0% | +27.4% |
| alltime | all time | -101.6% | at low | -99.8% | +111.4% | -101.0% | +27.4% |
BCRX Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $529.00K(-113.2%) | -$4.18M(-27.4%) |
| Dec 2024 | -$5.76M(-117.7%) | -$4.02M(-415.6%) | -$5.76M(+17.3%) |
| Sep 2024 | - | $1.27M(-164.8%) | -$4.91M(-1.0%) |
| Jun 2024 | - | -$1.97M(+87.6%) | -$4.96M(-118.8%) |
| Mar 2024 | - | -$1.05M(-67.0%) | $26.36M(-18.9%) |
| Dec 2023 | $32.48M(-63.1%) | -$3.17M(-359.0%) | $32.48M(-18.5%) |
| Sep 2023 | - | $1.23M(-95.8%) | $39.86M(-65.3%) |
| Jun 2023 | - | $29.36M(+478.2%) | $114.96M(+34.1%) |
| Mar 2023 | - | $5.08M(+20.9%) | $85.75M(-2.6%) |
| Dec 2022 | $88.03M(-75.5%) | $4.20M(-94.5%) | $88.03M(-79.6%) |
| Sep 2022 | - | $76.33M(>+9900.0%) | $431.25M(+19.9%) |
| Jun 2022 | - | $147.00K(-98.0%) | $359.70M(-1.2%) |
| Mar 2022 | - | $7.36M(-97.9%) | $364.12M(+1.2%) |
| Dec 2021 | $359.67M(+19.7%) | $347.42M(+7174.2%) | $359.67M(+72.1%) |
| Sep 2021 | - | $4.78M(+4.4%) | $209.01M(+4.7%) |
| Jun 2021 | - | $4.57M(+57.7%) | $199.60M(-34.2%) |
| Mar 2021 | - | $2.90M(-98.5%) | $303.22M(+0.9%) |
| Dec 2020 | $300.59M(+203.3%) | $196.76M(-4346.0%) | $300.59M(+64.9%) |
| Sep 2020 | - | -$4.63M(-104.3%) | $182.29M(-2.6%) |
| Jun 2020 | - | $108.20M(>+9900.0%) | $187.11M(+135.9%) |
| Mar 2020 | - | $266.00K(-99.7%) | $79.32M(-20.0%) |
| Dec 2019 | $99.10M(+58.5%) | $78.46M(>+9900.0%) | $99.10M(+351.0%) |
| Sep 2019 | - | $184.00K(-55.6%) | $21.98M(-74.4%) |
| Jun 2019 | - | $414.00K(-97.9%) | $85.71M(+2.0%) |
| Mar 2019 | - | $20.04M(+1398.9%) | $84.02M(+34.4%) |
| Dec 2018 | $62.50M(-53.9%) | $1.34M(-97.9%) | $62.50M(+1.2%) |
| Sep 2018 | - | $63.92M(-5113.2%) | $61.74M(-26.6%) |
| Jun 2018 | - | -$1.27M(-13.6%) | $84.13M(-1.6%) |
| Mar 2018 | - | -$1.48M(-357.6%) | $85.53M(-37.0%) |
| Dec 2017 | $135.70M(+482.3%) | $573.00K(-99.3%) | $135.70M(-1.3%) |
| Sep 2017 | - | $86.31M(>+9900.0%) | $137.46M(+87.1%) |
| Jun 2017 | - | $118.00K(-99.8%) | $73.48M(+2.3%) |
| Mar 2017 | - | $48.70M(+1988.3%) | $71.87M(+208.4%) |
| Dec 2016 | $23.30M(+325.3%) | $2.33M(-89.6%) | $23.30M(+10.7%) |
| Sep 2016 | - | $22.34M(-1588.0%) | $21.06M(-3448.0%) |
| Jun 2016 | - | -$1.50M(-1187.7%) | -$629.00K(-115.3%) |
| Mar 2016 | - | $138.00K(+58.6%) | $4.12M(-24.9%) |
| Dec 2015 | $5.48M(-95.1%) | $87.00K(-86.6%) | $5.48M(-4.8%) |
| Sep 2015 | - | $647.00K(-80.1%) | $5.75M(-32.2%) |
| Jun 2015 | - | $3.24M(+116.1%) | $8.48M(-92.4%) |
| Mar 2015 | - | $1.50M(+315.8%) | $111.01M(-0.8%) |
| Dec 2014 | $111.91M(+269.7%) | $361.00K(-89.3%) | $111.91M(-1.3%) |
| Sep 2014 | - | $3.37M(-96.8%) | $113.44M(-12.8%) |
| Jun 2014 | - | $105.77M(+4303.5%) | $130.08M(+339.0%) |
| Mar 2014 | - | $2.40M(+27.0%) | $29.63M(-2.1%) |
| Dec 2013 | $30.27M(+78.5%) | $1.89M(-90.6%) | $30.27M(+5.5%) |
| Sep 2013 | - | $20.01M(+275.8%) | $28.70M(+165.3%) |
| Jun 2013 | - | $5.33M(+75.2%) | $10.82M(+34.0%) |
| Mar 2013 | - | $3.04M(+862.0%) | $8.07M(-52.4%) |
| Dec 2012 | $16.96M(-28.6%) | $316.00K(-85.2%) | $16.96M(-2.1%) |
| Sep 2012 | - | $2.14M(-17.2%) | $17.32M(+17.5%) |
| Jun 2012 | - | $2.58M(-78.3%) | $14.75M(+29.5%) |
| Mar 2012 | - | $11.93M(+1656.3%) | $11.39M(-52.0%) |
| Dec 2011 | $23.75M(+2758.6%) | $679.00K(-254.7%) | $23.75M(+2.3%) |
| Sep 2011 | - | -$439.00K(-43.2%) | $23.22M(-2.4%) |
| Jun 2011 | - | -$773.00K(-103.2%) | $23.78M(-4.0%) |
| Mar 2011 | - | $24.29M(>+9900.0%) | $24.77M(+2880.9%) |
| Dec 2010 | $831.00K(-98.3%) | $145.00K(+19.8%) | $831.00K(-98.2%) |
| Sep 2010 | - | $121.00K(-44.2%) | $46.98M(-2.9%) |
| Jun 2010 | - | $217.00K(-37.6%) | $48.36M(+0.4%) |
| Mar 2010 | - | $348.00K(-99.2%) | $48.15M(+0.5%) |
| Dec 2009 | $47.90M | $46.29M(+2981.9%) | $47.90M(+2835.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2009 | - | $1.50M(>+9900.0%) | $1.63M(+452.0%) |
| Jun 2009 | - | $14.00K(-84.4%) | $295.60K(+5.0%) |
| Mar 2009 | - | $90.00K(+251.6%) | $281.60K(-57.8%) |
| Dec 2008 | $666.60K(-99.0%) | $25.60K(-84.6%) | $666.60K(-1.1%) |
| Sep 2008 | - | $166.00K(>+9900.0%) | $673.90K(-99.0%) |
| Jun 2008 | - | $0.00(-100.0%) | $66.04M(-1.4%) |
| Mar 2008 | - | $475.00K(+1343.8%) | $66.95M(+0.3%) |
| Dec 2007 | $66.77M(+2154.8%) | $32.90K(-99.9%) | $66.77M(-0.1%) |
| Sep 2007 | - | $65.53M(+7109.4%) | $66.84M(+4566.9%) |
| Jun 2007 | - | $909.00K(+209.2%) | $1.43M(+41.4%) |
| Mar 2007 | - | $294.00K(+184.9%) | $1.01M(-65.8%) |
| Dec 2006 | $2.96M(-94.6%) | $103.20K(-18.1%) | $2.96M(-91.3%) |
| Sep 2006 | - | $126.00K(-74.3%) | $34.05M(-3.0%) |
| Jun 2006 | - | $490.00K(-78.1%) | $35.10M(+1.4%) |
| Mar 2006 | - | $2.24M(-92.8%) | $34.61M(-37.3%) |
| Dec 2005 | $55.18M(+156.9%) | $31.19M(+2543.1%) | $55.18M(+128.8%) |
| Sep 2005 | - | $1.18M(>+9900.0%) | $24.11M(+4.3%) |
| Jun 2005 | - | $0.00(-100.0%) | $23.13M(-3.1%) |
| Mar 2005 | - | $22.81M(>+9900.0%) | $23.86M(+11.1%) |
| Dec 2004 | $21.48M(+2287.3%) | $122.80K(-36.4%) | $21.48M(-3.3%) |
| Sep 2004 | - | $193.00K(-73.7%) | $22.22M(+0.7%) |
| Jun 2004 | - | $733.00K(-96.4%) | $22.06M(+3.4%) |
| Mar 2004 | - | $20.43M(+2273.6%) | $21.32M(+2270.1%) |
| Dec 2003 | $899.70K(+633.8%) | $860.70K(+2508.2%) | $899.70K(+2230.8%) |
| Sep 2003 | - | $33.00K(>+9900.0%) | $38.60K(+39.9%) |
| Jun 2003 | - | $0.00(-100.0%) | $27.60K(0.0%) |
| Mar 2003 | - | $6000.00(-1600.0%) | $27.60K(-77.5%) |
| Dec 2002 | $122.60K(-34.1%) | -$400.00(-101.8%) | $122.60K(-19.9%) |
| Sep 2002 | - | $22.00K(>+9900.0%) | $153.00K(-45.0%) |
| Jun 2002 | - | $0.00(-100.0%) | $278.00K(+1.5%) |
| Mar 2002 | - | $101.00K(+236.7%) | $274.00K(+47.3%) |
| Dec 2001 | $186.00K(-87.9%) | $30.00K(-79.6%) | $186.00K(-28.0%) |
| Sep 2001 | - | $147.00K(-3775.0%) | $258.40K(-17.0%) |
| Jun 2001 | - | -$4000.00(-130.8%) | $311.40K(-49.0%) |
| Mar 2001 | - | $13.00K(-87.3%) | $610.40K(-60.3%) |
| Dec 2000 | $1.54M(-96.9%) | $102.40K(-48.8%) | $1.54M(-96.8%) |
| Sep 2000 | - | $200.00K(-32.2%) | $48.44M(-3.4%) |
| Jun 2000 | - | $295.00K(-68.7%) | $50.14M(+0.6%) |
| Mar 2000 | - | $941.00K(-98.0%) | $49.84M(+1.7%) |
| Dec 1999 | $49.00M(+610.1%) | $47.00M(+2373.7%) | $49.00M(+490.4%) |
| Sep 1999 | - | $1.90M(>+9900.0%) | $8.30M(+27.7%) |
| Jun 1999 | - | $0.00(-100.0%) | $6.50M(0.0%) |
| Mar 1999 | - | $100.00K(-98.4%) | $6.50M(-5.8%) |
| Dec 1998 | $6.90M(+3350.0%) | $6.30M(+6200.0%) | $6.90M(+1050.0%) |
| Sep 1998 | - | $100.00K(>+9900.0%) | $600.00K(0.0%) |
| Jun 1998 | - | $0.00(-100.0%) | $600.00K(+20.0%) |
| Mar 1998 | - | $500.00K(>+9900.0%) | $500.00K(+150.0%) |
| Dec 1997 | $200.00K(-99.4%) | $0.00(-100.0%) | $200.00K(-99.1%) |
| Sep 1997 | - | $100.00K(-200.0%) | $22.60M(+2.3%) |
| Jun 1997 | - | -$100.00K(-150.0%) | $22.10M(-6.8%) |
| Mar 1997 | - | $200.00K(-99.1%) | $23.70M(-24.8%) |
| Dec 1996 | $31.50M(+275.0%) | $22.40M(-5700.0%) | $31.50M(+250.0%) |
| Sep 1996 | - | -$400.00K(-126.7%) | $9.00M(-4.3%) |
| Jun 1996 | - | $1.50M(-81.3%) | $9.40M(-43.0%) |
| Mar 1996 | - | $8.00M(-8100.0%) | $16.50M(+96.4%) |
| Dec 1995 | $8.40M(-43.6%) | -$100.00K(<-9900.0%) | $8.40M(0.0%) |
| Sep 1995 | - | $0.00(-100.0%) | $8.40M(-18.4%) |
| Jun 1995 | - | $8.60M(-8700.0%) | $10.30M(+543.8%) |
| Mar 1995 | - | -$100.00K(0.0%) | $1.60M(-89.3%) |
| Dec 1994 | $14.90M | -$100.00K(-105.3%) | $14.90M(-0.7%) |
| Sep 1994 | - | $1.90M(-2000.0%) | $15.00M(+14.5%) |
| Jun 1994 | - | -$100.00K(-100.8%) | $13.10M(-0.8%) |
| Mar 1994 | - | $13.20M | $13.20M |
FAQ
- What is BioCryst Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals annual CFF year-on-year change?
- What is BioCryst Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly CFF year-on-year change?
- What is BioCryst Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM CFF year-on-year change?
What is BioCryst Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of BCRX is -$5.76M
What is the all time high annual CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual cash flow from financing activities is $359.67M
What is BioCryst Pharmaceuticals annual CFF year-on-year change?
Over the past year, BCRX annual cash flow from financing activities has changed by -$38.25M (-117.73%)
What is BioCryst Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of BCRX is $529.00K
What is the all time high quarterly CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly cash flow from financing activities is $347.42M
What is BioCryst Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, BCRX quarterly cash flow from financing activities has changed by +$1.58M (+150.48%)
What is BioCryst Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of BCRX is -$4.18M
What is the all time high TTM CFF for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM cash flow from financing activities is $431.25M
What is BioCryst Pharmaceuticals TTM CFF year-on-year change?
Over the past year, BCRX TTM cash flow from financing activities has changed by -$30.54M (-115.87%)